- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
Patent holdings for IPC class C07D 239/47
Total number of patents in this class: 738
10-year publication summary
|
53
|
56
|
53
|
51
|
44
|
38
|
26
|
26
|
37
|
19
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| ADAMA Makhteshim Ltd. | 561 |
44 |
| Bristol-myers Squibb Company | 4742 |
25 |
| Novartis AG | 10262 |
20 |
| Oxular Acquisitions Limited | 21 |
14 |
| Boehringer Ingelheim International GmbH | 4493 |
13 |
| Corteva Agriscience LLC | 2648 |
12 |
| Carnegie Mellon University | 1623 |
11 |
| Eli Lilly and Company | 4101 |
10 |
| Celgene Quanticel Research, Inc. | 154 |
8 |
| Emergent BioDefense Operations Lansing LLC | 32 |
8 |
| Shionogi & Co., Ltd. | 880 |
8 |
| Genentech, Inc. | 4104 |
7 |
| Merck Patent GmbH | 5728 |
7 |
| Actelion Pharmaceuticals Ltd | 496 |
7 |
| Curza Global, LLC | 28 |
7 |
| Kowa Company, Ltd. | 1235 |
7 |
| Ono Pharmaceutical Co., Ltd. | 421 |
7 |
| University of Utah Research Foundation | 1862 |
7 |
| Dana-Farber Cancer Institute, Inc. | 2664 |
6 |
| Ocuphire Pharma, Inc. | 22 |
6 |
| Other owners | 504 |